Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Rapt Therapeutics Inc RAPT

Healthcare Biotechnology
RAPT Therapeutics, Inc. is a clinical-stage immunology-based biopharmaceutical company. The Company is focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology. Utilizing its drug discovery and development engine, it develops selective small molecules designed to modulate the critical immune responses underlying these diseases. Its lead inflammation drug candidate, zelnecirnon (RPT193), and its lead oncology drug candidate, tivumecirnon (FLX475), each target C-C motif chemokine receptor 4 (CCR4), a drug target that potentially has broad applicability in inflammatory diseases and oncology. Its inflammation drug candidate, zelnecirnon, is designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues. Its oncology drug candidate, tivumecirnon, is designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors.


NDAQ:RAPT - Post by User

Rapt Therapeutics Inc
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(228)
•••
Post by whytestockson Feb 20, 2024 5:15pm
54 Views
Post# 35889749

Why Is Inflammatory Disease/Oncology-Focused RAPT Therapeuti

Why Is Inflammatory Disease/Oncology-Focused RAPT Therapeuti
News; $RAPT Why Is Inflammatory Disease/Oncology-Focused RAPT Therapeutics Shares Tumbling Today? | BenzingaTuesday, the FDA verbally notified&nbsp;RAPT Therapeutics Inc&nbsp;(NASDAQ:RAPT) that a clinical hold has been placed on the company&#8217;s Phase ...RAPT - Why Is Inflammatory Disease/Oncology-Focused RAPT Therapeutics Shares Tumbling Today? | Benzinga

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities